Regarding safety, integrin inhibitors generally present a lower risk of infections and malignancies compared to anti-TNF therapy [311], However, case reports have indicated that vedolizumab may be associated with rare pulmonary inflammation (eosinophilic pneumonia) or virus-associated malignancies [312, 313]. This evidence concerns the gene TNF and infection.